Changyu Zhu1, Yu-Jui Ho2, Marcela A Salomao3, Dianne H Dapito4, Alberto Bartolome4, Robert F Schwabe4, Ju-Seog Lee5, Scott W Lowe6, Utpal B Pajvani7. 1. Department of Medicine, Columbia University, New York, NY, USA; Department of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ, USA. 4. Department of Medicine, Columbia University, New York, NY, USA. 5. Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Department of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA. 7. Department of Medicine, Columbia University, New York, NY, USA. Electronic address: up2104@columbia.edu.
Abstract
BACKGROUND & AIMS: The hepatocyte Notch pathway is a pathogenic factor in non-alcoholic steatohepatitis (NASH)-associated fibrosis, but its role in hepatocellular carcinoma (HCC) is less well defined. Herein, we aimed to characterize the molecular and clinical features of Notch-active human HCC, and to investigate the mechanisms by which Notch affects NASH-driven HCC. METHODS: Using a 14-gene Notch score, we stratified human HCCs from multiple comprehensively profiled datasets. We performed gene set enrichment analyses to compare Notch-active HCCs with published HCC subtype signatures. Next, we sorted Notch-active hepatocytes from Notch reporter mice for RNA sequencing and characterized Notch-active tumors in an HCC model combining a carcinogen and a NASH-inducing diet. We used genetic mouse models to manipulate hepatocyte Notch to investigate the sufficiency and necessity of Notch in NASH-driven tumorigenesis. RESULTS: Notch-active signatures were found in ~30% of human HCCs that transcriptionally resemble cholangiocarcinoma-like HCC, exhibiting a lack of activating CTNNB1 (β-catenin) mutations and a generally poor prognosis. Endogenous Notch activation in hepatocytes is associated with repressed β-catenin signaling and hepatic metabolic functions, in lieu of increased interactions with the extracellular matrix in NASH. Constitutive hepatocyte Notch activation is sufficient to induce β-catenin-inactive HCC in mice with NASH. Notch and β-catenin show a pattern of mutual exclusivity in carcinogen-induced HCC; in this mouse model, chronic blockade of Notch led to β-catenin-dependent tumor development. CONCLUSIONS: Notch activity characterizes a distinct HCC molecular subtype with unique histology and prognosis. Sustained Notch signaling in chronic liver diseases can drive tumor formation without acquiring specific genomic driver mutations. LAY SUMMARY: The Notch signaling pathway is known to be involved in the pathogenesis of liver fibrosis. However, its role in liver cancer has not been well defined. Herein, we show that Notch activity is increased in a subset of liver cancers and is associated with poor outcomes. We also used a mouse model to show that aberrant Notch activity can drive cancer progression in obese mice.
BACKGROUND & AIMS: The hepatocyte Notch pathway is a pathogenic factor in non-alcoholic steatohepatitis (NASH)-associated fibrosis, but its role in hepatocellular carcinoma (HCC) is less well defined. Herein, we aimed to characterize the molecular and clinical features of Notch-active human HCC, and to investigate the mechanisms by which Notch affects NASH-driven HCC. METHODS: Using a 14-gene Notch score, we stratified human HCCs from multiple comprehensively profiled datasets. We performed gene set enrichment analyses to compare Notch-active HCCs with published HCC subtype signatures. Next, we sorted Notch-active hepatocytes from Notch reporter mice for RNA sequencing and characterized Notch-active tumors in an HCC model combining a carcinogen and a NASH-inducing diet. We used genetic mouse models to manipulate hepatocyte Notch to investigate the sufficiency and necessity of Notch in NASH-driven tumorigenesis. RESULTS: Notch-active signatures were found in ~30% of human HCCs that transcriptionally resemble cholangiocarcinoma-like HCC, exhibiting a lack of activating CTNNB1 (β-catenin) mutations and a generally poor prognosis. Endogenous Notch activation in hepatocytes is associated with repressed β-catenin signaling and hepatic metabolic functions, in lieu of increased interactions with the extracellular matrix in NASH. Constitutive hepatocyte Notch activation is sufficient to induce β-catenin-inactive HCC in mice with NASH. Notch and β-catenin show a pattern of mutual exclusivity in carcinogen-induced HCC; in this mouse model, chronic blockade of Notch led to β-catenin-dependent tumor development. CONCLUSIONS: Notch activity characterizes a distinct HCC molecular subtype with unique histology and prognosis. Sustained Notch signaling in chronic liver diseases can drive tumor formation without acquiring specific genomic driver mutations. LAY SUMMARY: The Notch signaling pathway is known to be involved in the pathogenesis of liver fibrosis. However, its role in liver cancer has not been well defined. Herein, we show that Notch activity is increased in a subset of liver cancers and is associated with poor outcomes. We also used a mouse model to show that aberrant Notch activity can drive cancer progression in obese mice.
Authors: Andrew P Weng; Adolfo A Ferrando; Woojoong Lee; John P Morris; Lewis B Silverman; Cheryll Sanchez-Irizarry; Stephen C Blacklow; A Thomas Look; Jon C Aster Journal: Science Date: 2004-10-08 Impact factor: 47.728
Authors: Ju-Seog Lee; Jeonghoon Heo; Louis Libbrecht; In-Sun Chu; Pal Kaposi-Novak; Diego F Calvisi; Arsen Mikaelyan; Lewis R Roberts; Anthony J Demetris; Zongtang Sun; Frederik Nevens; Tania Roskams; Snorri S Thorgeirsson Journal: Nat Med Date: 2006-03-12 Impact factor: 53.440
Authors: Derek Y Chiang; Augusto Villanueva; Yujin Hoshida; Judit Peix; Philippa Newell; Beatriz Minguez; Amanda C LeBlanc; Diana J Donovan; Swan N Thung; Manel Solé; Victoria Tovar; Clara Alsinet; Alex H Ramos; Jordi Barretina; Sasan Roayaie; Myron Schwartz; Samuel Waxman; Jordi Bruix; Vincenzo Mazzaferro; Azra H Ligon; Vesna Najfeld; Scott L Friedman; William R Sellers; Matthew Meyerson; Josep M Llovet Journal: Cancer Res Date: 2008-08-15 Impact factor: 12.701
Authors: Richard A Moffitt; Raoud Marayati; Elizabeth L Flate; Keith E Volmar; S Gabriela Herrera Loeza; Katherine A Hoadley; Naim U Rashid; Lindsay A Williams; Samuel C Eaton; Alexander H Chung; Jadwiga K Smyla; Judy M Anderson; Hong Jin Kim; David J Bentrem; Mark S Talamonti; Christine A Iacobuzio-Donahue; Michael A Hollingsworth; Jen Jen Yeh Journal: Nat Genet Date: 2015-09-07 Impact factor: 38.330
Authors: Xiaobo Wang; Sharon Zeldin; Hongxue Shi; Changyu Zhu; Yoshinobu Saito; Kathleen E Corey; Stephanie A Osganian; Helen E Remotti; Elizabeth C Verna; Utpal B Pajvani; Robert F Schwabe; Ira Tabas Journal: J Hepatol Date: 2021-12-11 Impact factor: 30.083
Authors: Caio Bezerra Machado; Leidivan Sousa da Cunha; Jersey Heitor da Silva Maués; Flávia Melo Cunha de Pinho Pessoa; Marcelo Braga de Oliveira; Rodrigo Monteiro Ribeiro; Germison Silva Lopes; Manoel Odorico de Moraes Filho; Maria Elisabete Amaral de Moraes; André Salim Khayat; Caroline Aquino Moreira-Nunes Journal: Int J Mol Sci Date: 2022-05-14 Impact factor: 6.208
Authors: Yuquan Qian; Jimmy Daza; Timo Itzel; Johannes Betge; Tianzuo Zhan; Frederik Marmé; Andreas Teufel Journal: Cells Date: 2021-03-15 Impact factor: 6.600